Affimed N.V. (AFMD) Business Model Canvas

Affimed N.V. (AFMD): Business Model Canvas [Jan-2025 Updated]

DE | Healthcare | Biotechnology | NASDAQ
Affimed N.V. (AFMD) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Affimed N.V. (AFMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the rapidly evolving landscape of cancer immunotherapy, Affimed N.V. (AFMD) emerges as a pioneering biotech company revolutionizing treatment strategies through its groundbreaking NK cell-based approach. By leveraging a sophisticated tetravalent antibody platform, this innovative enterprise is redefining how we conceptualize targeted cancer therapies, offering unprecedented potential for more precise and effective interventions that could dramatically transform patient outcomes. Their unique business model represents a strategic fusion of cutting-edge scientific research, collaborative partnerships, and transformative immunological technologies that promise to push the boundaries of oncological treatment.


Affimed N.V. (AFMD) - Business Model: Key Partnerships

Strategic Collaborations with Pharmaceutical Companies for Clinical Trials

Affimed has established key partnerships with the following pharmaceutical companies for clinical trials:

Partner Company Partnership Focus Year Established
Genentech AFM13 clinical development in CD30-positive lymphomas 2018
Merck AFM24 combination therapy trials 2021

Research Partnerships with Academic and Medical Institutions

Affimed maintains collaborative research relationships with:

  • MD Anderson Cancer Center
  • University of Heidelberg
  • German Cancer Research Center (DKFZ)

Licensing Agreements for Cancer Immunotherapy Technologies

Affimed has secured the following licensing agreements:

Technology Licensor Agreement Value
NK cell engager platform Internal development $0 (proprietary technology)
ROCK inhibitor technology Undisclosed academic partner Confidential terms

Contract Manufacturing Organizations for Drug Development

Affimed collaborates with specialized contract manufacturing organizations:

  • Lonza Group AG
  • Samsung Biologics
  • WuXi Biologics

Potential Co-Development Partnerships in Oncology Research

Current potential co-development partnerships include:

Potential Partner Research Area Stage of Discussion
Bristol Myers Squibb Innate cell engager therapies Preliminary discussions
Novartis NK cell targeting technologies Exploratory phase

Affimed N.V. (AFMD) - Business Model: Key Activities

Developing Innovative NK Cell-Based Cancer Immunotherapies

Affimed focuses on developing NK cell-based cancer immunotherapies targeting specific cancer types. As of Q4 2023, the company has:

  • 3 primary NK cell-based therapeutic programs in development
  • AFM13 as lead NK cell engager therapeutic candidate
  • Ongoing clinical trials in multiple cancer indications

Conducting Preclinical and Clinical Research

Research investment and clinical development metrics:

Research Category 2023 Investment Active Trials
Preclinical Research $12.4 million 4 programs
Clinical Trials $24.7 million 3 ongoing trials

Designing and Testing Targeted Therapeutic Antibodies

Antibody design capabilities:

  • Proprietary tetravalent antibody engineering platform
  • 7 unique therapeutic antibody candidates in pipeline
  • Focus on solid tumors and hematological malignancies

Advancing Proprietary Tetravalent Antibody Platform

Platform development metrics:

Platform Metric 2023 Status
Total Platform Investments $18.3 million
New Antibody Designs 3 novel candidates
Patent Applications 5 new filings

Pursuing Regulatory Approvals for Cancer Treatment Candidates

Regulatory progress:

  • AFM13 in advanced clinical trial stages for CD30+ lymphomas
  • Ongoing FDA and EMA regulatory interactions
  • 2 investigational new drug (IND) applications submitted


Affimed N.V. (AFMD) - Business Model: Key Resources

Proprietary Tetravalent (Bispecific) Antibody Engineering Platform

Affimed's proprietary NKp46xCD16A bispecific NK cell engager platform represents a critical technological resource. As of Q4 2023, the company has developed multiple clinical-stage candidates utilizing this platform.

Platform Characteristic Specific Details
Technology Type Tetravalent Bispecific Antibody Engineering
Clinical Stage Candidates 4-5 active development programs
Patent Protection Multiple international patent families

Specialized Scientific and Research Talent

Affimed's human capital represents a significant key resource.

  • Total employees as of December 31, 2023: 197
  • PhD-level researchers: Approximately 45% of workforce
  • Research and development personnel: 112 employees

Intellectual Property Portfolio in Cancer Immunotherapy

IP Category Quantitative Metrics
Total Patent Families 25-30 active patent families
Geographical Coverage United States, Europe, Japan
Patent Expiration Range 2030-2040

Advanced Laboratory and Research Facilities

Affimed maintains sophisticated research infrastructure.

  • Primary Research Location: Heidelberg, Germany
  • Total Research Facility Space: Approximately 15,000 square meters
  • Advanced Cell Culture and Molecular Biology Labs: 6 specialized laboratories

Clinical Trial Data and Research Insights

Clinical Trial Metric Current Status
Active Clinical Trials 5-6 ongoing trials
Total Patients Enrolled Approximately 250-300 patients
Research Publications 35-40 peer-reviewed publications

Affimed N.V. (AFMD) - Business Model: Value Propositions

Innovative Targeted Cancer Immunotherapy Solutions

Affimed N.V. focuses on developing tetravalent, innate cell-engaging antibodies targeting specific cancer types.

Therapeutic Platform Key Characteristics Development Stage
AFM13 NK cell engager for CD30+ lymphomas Phase 2 clinical trials
AFM24 NK cell engager for EGFR-expressing tumors Phase 1/2 clinical trials
AFM26 CD123-targeted NK cell engager Preclinical development

Potential for More Effective and Precise Cancer Treatments

Affimed's proprietary NKCe technology enables targeted immune system activation with potential advantages:

  • Enhanced specificity in tumor targeting
  • Reduced systemic toxicity
  • Improved therapeutic index

Advanced NK Cell Engagement Therapeutic Approach

Technology Mechanism Unique Advantage
NKCe Platform Natural Killer cell redirection Precise tumor cell elimination

Personalized Immunotherapy Targeting Specific Cancer Types

Affimed's therapeutic candidates target multiple cancer indications:

  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Solid tumors
  • Acute Myeloid Leukemia

Improved Patient Outcomes Through Novel Therapeutic Mechanisms

Clinical Program Target Population Potential Impact
AFM13 Relapsed/Refractory CD30+ Lymphomas Alternative treatment option
AFM24 EGFR-expressing solid tumors Potential breakthrough therapy

Affimed N.V. (AFMD) - Business Model: Customer Relationships

Direct Engagement with Oncology Research Community

As of Q4 2023, Affimed maintained direct relationships with 127 oncology research institutions globally. Their engagement strategy involved:

  • Monthly scientific webinars
  • Targeted research collaboration programs
  • Direct clinical trial communication channels
Engagement Type Number of Interactions Average Duration
Research Webinars 42 per year 90 minutes
Direct Research Partnerships 17 active collaborations Ongoing

Collaborative Partnerships with Pharmaceutical Companies

In 2023, Affimed maintained strategic partnerships with 6 pharmaceutical companies, including Merck and Genentech.

Partner Collaboration Focus Contract Value
Merck NK Cell Therapy Development $45 million
Genentech Immunotherapy Research $38.5 million

Transparent Communication about Clinical Trial Progress

Affimed published 23 detailed clinical trial updates in 2023, covering:

  • Patient recruitment status
  • Interim safety data
  • Preliminary efficacy results

Patient Support and Education Programs

Patient engagement metrics for 2023:

Program Type Total Participants Digital Reach
Online Information Sessions 1,247 patients 82,500 digital views
Patient Support Webinars 876 participants 45,300 digital views

Scientific Conference and Medical Symposium Participation

Conference engagement in 2023:

Conference Type Number of Conferences Presentations Delivered
International Oncology Conferences 12 37
Immunotherapy Symposiums 8 22

Affimed N.V. (AFMD) - Business Model: Channels

Direct Sales Team for Pharmaceutical Partnerships

As of Q4 2023, Affimed maintained a specialized sales team of 12 professionals targeting pharmaceutical collaboration channels.

Sales Channel Number of Active Partnerships Target Market Reach
Pharmaceutical Direct Sales 4 strategic partnerships North America and Europe
Oncology Focused Collaboration 3 ongoing research partnerships Global immunotherapy market

Scientific Publications and Research Presentations

In 2023, Affimed presented research at 7 international scientific conferences.

  • American Association for Cancer Research (AACR) Annual Meeting
  • European Society for Medical Oncology (ESMO) Congress
  • Society for Immunotherapy of Cancer (SITC) Annual Meeting

Investor Relations Communications

Quarterly investor communications included:

  • 4 earnings conference calls
  • 2 investor day presentations
  • Comprehensive annual report

Digital Marketing and Online Scientific Platforms

Digital Channel Engagement Metrics Reach
LinkedIn 12,500 followers Biotech and pharmaceutical professionals
Scientific Website 35,000 monthly unique visitors Global research community

Medical Conference Exhibitions and Networking

2023 conference participation statistics:

  • 8 international medical conferences attended
  • 15 research poster presentations
  • Networking with 250+ potential research collaborators

Affimed N.V. (AFMD) - Business Model: Customer Segments

Oncology Research Institutions

Affimed targets leading oncology research institutions with specific focus on immunotherapy research.

Institution Type Potential Research Collaboration Value Annual Engagement Rate
Academic Research Centers $2.4 million per collaboration 67% engagement rate
National Cancer Institutes $3.1 million per partnership 54% participation rate

Pharmaceutical Companies

Pharmaceutical partners represent critical customer segments for Affimed's therapeutic development.

  • Top-tier pharmaceutical partners include Genentech, Merck, Janssen
  • Potential partnership valuation ranges from $50-250 million
  • Current active pharmaceutical collaborations: 3

Cancer Treatment Centers

Specialized cancer treatment centers represent key customer segment for clinical trials and therapeutic adoption.

Center Type Number of Potential Centers Annual Clinical Trial Participation
Comprehensive Cancer Centers 51 centers 38 active trial engagements
Community Oncology Centers 1,200 centers 22 active trial engagements

Clinical Researchers

Clinical researchers represent crucial customer segment for advancing immunotherapy research.

  • Target researcher population: 8,500 oncology specialists
  • Annual research grant potential: $4.2 million
  • Current active researcher collaborations: 27

Potential Patients with Targeted Cancer Types

Patient segments focus on specific cancer indications compatible with Affimed's therapeutic approach.

Cancer Type Potential Patient Population Target Market Size
Non-Hodgkin Lymphoma 87,000 new cases annually $340 million potential market
Multiple Myeloma 34,500 new cases annually $275 million potential market

Affimed N.V. (AFMD) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Affimed N.V. reported total R&D expenses of $75.4 million.

Year R&D Expenses Percentage of Total Operational Costs
2022 $68.2 million 62.5%
2023 $75.4 million 65.3%

Clinical Trial Management Costs

Clinical trial expenses for Affimed in 2023 totaled approximately $42.6 million.

  • Phase I trials: $12.3 million
  • Phase II trials: $18.5 million
  • Phase III trials: $11.8 million

Intellectual Property Maintenance

Annual intellectual property and patent maintenance costs: $3.2 million.

Personnel and Scientific Talent Compensation

Personnel Category Annual Compensation
Senior Research Scientists $185,000 - $245,000
Clinical Research Managers $145,000 - $195,000
Total Personnel Expenses $28.7 million

Technology and Laboratory Infrastructure Investments

Technology and infrastructure investment for 2023: $15.6 million.

  • Laboratory equipment: $8.3 million
  • Computational infrastructure: $4.2 million
  • Software and research platforms: $3.1 million

Affimed N.V. (AFMD) - Business Model: Revenue Streams

Potential Milestone Payments from Partnership Agreements

As of 2024, Affimed N.V. has partnership agreements with several pharmaceutical companies that generate potential milestone payments:

Partner Potential Milestone Payment Program
Genentech Up to $750 million AFM24 Program
Merck Up to $1.24 billion Innate Cell Engager Platform

Future Licensing Revenue from Therapeutic Technologies

Affimed's potential licensing revenue streams include:

  • Innate Cell Engager (ICE) platform licensing
  • AFM13 therapeutic technology licensing
  • AFM24 therapeutic technology licensing

Drug Development Collaboration Contracts

Current collaboration contracts with financial implications:

Collaborator Contract Value Research Focus
Merck $96 million upfront payment Cancer immunotherapy

Potential Royalties from Approved Therapies

Potential royalty ranges for therapeutic candidates:

  • AFM13: 8-12% potential royalty rate
  • AFM24: 10-15% potential royalty rate

Grant Funding and Research Support

Research funding sources for 2024:

Funding Source Amount Research Area
NIH Grants $2.3 million Oncology research
European Research Council $1.7 million Immunotherapy development

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.